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Quality  of  Life
Abstract
Background:  Allergic  rhinitis  (AR)  and  asthma  are  two  common  chronic  diseases  that  often
coexist. There  is  a  need  for  a  validated  tool  to  evaluate  HRQoL  of  Portuguese  speakers  with
asthma and/or  rhinitis  patients  in  clinical  practice.
Objectives:  To  adapt  and  validate  RhinAsthma  Patient  Perspective  (RAPP)  in  Portuguese.
Methods:  The  RAPP  questionnaire  was  translated  into  Portuguese.  Asthmatics  with  comorbidi-
ties and  rhinitis  attending  the  allergy  department  of  Coimbra  University  Hospital  were  asked  to
complete the  Portuguese  translation  of  RAPP,  in  addition  to  the  SF-12,  ACT,  and  a  Symptoma-
tologic VAS  twice,  with  a  4-week  interval  between  visits.  During  Visit  2,  a  Global  Rating  Scale
(GRS) was  completed  to  assess  any  change  in  health  status.  Scale  dimensions,  internal  consis-
tency and  convergent  validity,  reliability,  discriminant  ability  and  responsiveness  to  change,  as
well as  Minimal  Clinical  Difference  were  assessed.
Results:  Factor  and  confirmatory  analysis  confirm  the  unidimensional  structure  of  the  question-
naire. Internal  consistency  has  been  shown  to  be  satisfactory  (0.82  visit  1  and  0.86  at  visit  2).
The tool  is  able  to  discriminate  between  patients  on  the  basis  of  asthma  severity,  asthma  con-
trol level,  and  rhinitis  severity;  convergent  validity  showed  a  significant  correlation  with  SF-2.46  and  0.42,  p  at  Visits  1  and  2).  An  ICC  of  0.97  and  a  CCC  =  0.94
ghly  reliable.  Responsiveness  was  shown  in  detecting  a  significant
es  (r  =  0.41,  p  <  0.01)  and  ACT  (r  =  −0.47,  p  <  0.01)  but  not  with  VAS.
s  2  points.Physical component  (r  =  −0
indicate that  the  tool  is  hi
association  with  GRS  chang
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Conclusions:  The  Portuguese  version  of  RAPP  has  been  demonstrated  to  have  good  measure-
ment properties  and  sensitivity  to  health  changes,  which  will  provide  a  valid,  reliable  and
standardized  HRQoL  measurement  in  patients  with  asthma  and  comorbid  allergic  rhinitis  in
clinical practice.
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llergic  rhinitis  (AR)  and  asthma  are  two  common  chronic
iseases  that  often  coexist:  up  to  80%  of  patients  with
sthma  suffer  from  AR,  while  10--40%  of  patients  with  AR
lso  have  asthma.1--4 These  diseases  represent  a  significant
ocio-economic  burden  on  both  individuals  and  society  as  a
hole  due  to  the  high  direct  and  indirect  costs.5 Moreover,
here  is  now  considerable  evidence  that  AR  and  asthma  sig-
ificantly  impair  Health  Related  Quality  of  Life  (HRQoL).  In
act,  the  availability  of  validated  questionnaires  has  assisted
he  measurement  of  the  impact  of  respiratory  allergies  from
 patient  perspective  and  has  produced  a  rich  literature  on
he  ways  that  asthma  and  AR  negatively  affect  patient  phys-
cal,  emotional,  mental  and  social  life.5,6 However,  if  HRQoL
as  become  increasingly  considered  as  an  outcome  mea-
ure  in  clinical  trials,  its  integration  into  routine  assessment
emains  challenging.  This  depends  primarily  on  the  lack  of
uestionnaires  that  are  specifically  validated  for  use  with
ndividual  patients.
RhinAsthma  Patient  Perspective  (RAPP)  is  a  validated  tool
f  8  questions,  available  in  Italian,7,8 that  provides  evalu-
tion  of  HRQoL  of  patients  with  asthma  and/or  rhinitis  in
linical  practice.  Patients  are  asked  to  grade  the  extent  to
hich  they  have  been  bothered  by  each  problem  during  the
revious  2  weeks  using  a  5-point  Likert-type  scale  (not  at
ll,  a  little,  quite,  a  lot,  and  very  much).  The  tool  is  sim-
le  to  complete  and  the  score  is  a  simple  sum  of  the  single
nswers  (range  8--40).  A  cutoff  point  of  15  demonstrated  the
est  sensitivity  and  specificity  in  discriminating  the  achieve-
ent  of  an  optimal  HRQoL.  The  RAPP  owns  the  psychometric
roperties  that  are  requested  for  the  use  of  an  instrument
ith  an  individual  patient.9,10
The  aim  of  this  study  was  to  cross-culturally  adapt  and
alidate  the  RAPP  in  Portuguese.  This  project  was  part  of
 larger  multinational  study  aimed  at  evaluating  the  psy-
hometric  properties  of  the  RAPP  in  five  countries  (Spain,
rance,  Portugal,  Poland  and  the  Philippines)  and  to  com-
are  HRQoL  in  the  countries  involved.
aterials and methods
he  process  of  cross-cultural  adaptation  was  conducted
ccording  to  international  guidelines  with  2  forward  and
ackward  translations.11 Once  the  Portuguese  version  was
btained,  patients  who  visited  the  Immunoallergology
epartment,  Coimbra  University  Hospital,  Portugal,  were
rospectively  enrolled  between  June  and  December  2017.
ata  was  collected  using  a  convenience  sampling  method.12
4
he  aim  was  to  include  150  patients.  The  inclusion  criteria
ere:  age  ≥18,  asthma  and/or  rhinitis  diagnosis  according
o  GINA  and  ARIA  guideline  and  willingness  to  be  enrolled
nto  the  study.  Patients  suffering  from  any  other  respiratory
r  ear--nose--throat  disorders  were  excluded.
The  study  was  approved  by  the  ethics  committee  of  the
niversity  of  Genoa  (approval  no.  P.R.  333REG2016)  and
atified  by  the  local  ethics  committee;  it  was  conducted
n  accordance  with  the  general  principles  of  Good  Clinical
ractice  and  the  Declaration  of  Helsinki  as  amended  in  Edin-
urgh  in  2000.  Each  patient  gave  written  informed  consent
o  participate  at  the  beginning  of  the  study.
Patients  were  assessed  twice,  with  a  4-week  interval
etween  visits.  At  the  first  visit,  a  physician  collected
 complete  and  accurate  medical  history  and  recorded
ngoing  therapy.  Their  last  available  spirometric  value
as  registered.  Smoking  status  was  collected  and  patients
ere  classified  as  current  smokers,  former  smokers  or
on-smokers.  At  each  visit  patients  filled  in  the  RAPP  ques-
ionnaire,  SF-12  to  assess  health  status,  asthma  control  test
ACT),  and  a  Symptomatologic  Visual  Analog  Scale  (VAS)  to
valuate  rhinitis  severity.  At  Visit  2,  a  Global  Rating  Scale
as  completed  to  evaluate  any  change  in  health  status.
In  order  to  validate  the  Portuguese  version  of  RAPP,  the
ollowing  psychometric  analyses  were  performed:
)  Scale’s  dimension  by  mean  of  explorative  and  con-
firmative  factor  analysis.13,14 In  more  detail,  the
Kaiser--Meyer--Olkin  (KMO)  test  was  adopted  to  ana-
lyze  the  feasibility  of  factor  analysis,  and  Bartlett’s
Test  of  Sphericity  was  chosen  to  test  for  null  hypothe-
sis  that  the  correlation  matrix  has  an  identity  matrix.
The  root-mean-square  error  of  approximation  (RMSEA),
comparative  fit  index  (CFI),  and  standardized  root  mean
squared  residual  (SRMR)  were  used  to  assess  fit.
)  Internal  consistency  was  measured  using  Cronbach’s
alpha  on  the  whole  test.  Values  >0.70  are  generally
considered  acceptable,15 whereas  higher  scores  are  rec-
ommended  for  use  in  an  individual  patient.16
)  Reliability  was  assessed  in  patients  with  a  stable  health
status  (GRS  =  0)  by  means  of  interclass  coefficient  (ICC)
and  Lin’s  concordance  correlation  coefficient  (CCC).17
Coefficients  of  0.70  for  group  comparisons  and  of  0.90
for  comparisons  within  individuals  are  recommended.13
)  Convergent  validity  was  evaluated  using  Spearman’s
between  RAPP  and  SF-12.  Correlations  ranged  from  0.4
to  0.8  confirm  the  convergent  validity.
pective  (RAPP):  Validation  and  assessment  75
Table  1  (RAPP)  discriminant  validity.
Rapp  score
Visit  1  Visit  2
Asthma
Mild  16.8  16.5
Moderate  14.4 14.2
Severe  18.3 18.5
p-value  0.035 0.016
ACT
Totally  controlled  14  13.1
Well controlled  17.1  16.4
Uncontrolled  21.4  23
p-value  <0.01  <0.01
Rhinitis
Intermittent  14.8  14.3
Persistent  17.8  17.7
p-value  0.003  0.001
Rhinitis  severity





between  smokers,  former  smokers,  and  nonsmokers  (ANOVA
Fisher’s  test.  Visit  1:  p  =  0.06;  Visit  2:  p  =  0.11)  nor  on  the
basis  of  level  of  education  (ANOVA  Fisher’s  test.  Visit1:
Table  2  The  MID  of  RAPP  obtained  with  the  ROC  analysis
with different  cutoff.
Cutoff  ≥  Sensitivity  Specificity
5  .977  .451
4 .977  .539The  Portuguese  version  of  Rhinitis  and  Asthma  Patient’s  Pers
5)  Discriminant  validity  was  assessed  by  means  of  ANOVA
(Fischer’s  test)  comparing  patients  according  to  ACT,
GINA  and  ARIA  classification  of  severity.
6)  Responsiveness  was  evaluated  by  analyzing  the  corre-
lation  between  changes  in  RAPP  scores  and  changes  in
GRS,  VAS  and  ACT  by  means  of  a  non-parametric  test
(Spearman  correlation  coefficient).
7)  Minimal  important  difference  (MID)  was  determined  by
applying  the  receiver  operating  characteristics  (ROC)
curve  method.  The  entire  cohort  for  one  dichotomization
point  (i.e.,  ‘no  change’  vs  ‘any  improvement  or  deterio-
ration’)  was  adopted.18
The  possible  effect  of  age,  education,  and  smoking  habits
on  patients’  answers  was  explored  by  means  of  Spearman’s
correlation  coefficient  and  ANOVA  Fischer’s  test.
The  frequency  distribution  of  answers  was  calculated  to
verify  whether  patients  were  using  the  entire  answer  scale.
Statistical analyses
Statistical  analyses  were  performed  using  IBM  SPSS  Statis-
tics,  version  24,  Armonk,  NY  while  confirmatory  factor
analysis  was  performed  using  Mplus  7.0  (Muthén  &  Muthén,
Los  Angeles,  CA).19
Results
The  validation  sample  consisted  of  149  patients  (65%
females).  The  mean  age  was  36.8  (age  range  18--81  years).
Of  the  respondents,  4.2%  were  current  smokers,  10.3%  for-
mer  smokers  and  85.5%  non-smokers.  Academic  degree  was
the  most  common  level  of  education  attained  (55.3%),  fol-
lowed  by  high  school  (36.6%),  secondary  school  (6.5%)  and
primary  school  (1.6%)  qualifications.  61.1%  of  patients  suf-
fered  from  persistent  asthma  and  38.9%  from  intermittent
asthma.  AR  was  classified  as  mild  intermittent  in  24.2%  of
all  cases,  moderate--severe  intermittent  in  3.6%,  mild  per-
sistent  in  14.8%,  and  moderate--severe  persistent  in  56.4%
according  to  ARIA  guidelines.1 The  ACT  score  at  Visit  1
showed  31.7%  to  be  totally  controlled,  49.7%  to  be  well  con-
trolled,  and  18.6%  to  be  uncontrolled.  The  effective  time
between  the  two  visits  was  28  ±  3  days.
The  mean  value  of  AR  and  asthma  quality  of  life  was
16.9  ±  5.5  at  visit  1  and  16.8  ±  5.6  at  visit  2.
1)  Scale  dimensions  confirmed  that  the  data  were  suitable
for  factor  analysis.  The  solution  revealed  a  unidimen-
sional  structure  that  absorbed  37.8%  of  the  total  variance
and  only  4  residuals  greater  than  |0.10|  at  visit  1  and
43.4%  of  the  total  variance  and  only  2  residuals  greater
than  |0.10|  at  visit  2.  The  unidimensional  structure  was
confirmed:  the  goodness-of-fit  indexes  were  all  satisfac-
tory  both  at  visit  1  (RMSEA  0.08,  SRMR  0.05,  CFI  0.91)
and  at  visit  2  (RMSEA  0.09,  SRMR  0.06,  CFI  0.90)
2)  Internal  consistency:  Cronbach  alpha  values  were  0.82  at
visit  1  and  0.86  at  visit  2,  both  satisfactory.
3)  Reliability  was  evaluated  in  43  patients  reporting  an
unchanged  health  status  (GRS  =  0)  showing  an  ICC  of  0.97
and  a  CCC  =  0.94.Moderate--severe  18.5  18.5
p-value  <0.01  <0.01
)  Convergent  validity:  correlations  between  RAPP  scores
and  the  Physical  Component  Score  of  SF-12  were  signif-
icant  both  at  Visit  1  (r  =  −0.42,  p  <  0.01)  and  at  Visit  2
(r  =  −0.46,  p  <  0.01),  while  correlations  were  not  signif-
icant  between  RAPP  and  the  Mental  Component  Score
of  SF-12  either  at  Visit  1  (r  =  −0.05,  n.s.) or  Visit  2
(r  =  −0.02,  n.s.).
) Discriminant  validity:  RAPP  was  able  to  discriminate
between  patients  on  the  basis  of  asthma  severity,  asthma
control  level,  and  rhinitis  severity  (Table  1).
)  Responsiveness  was  assessed  in  106  patients  with  a  health
improvement  or  deterioration,  evaluated  by  GRS  /=  0.
RAPP  was  significantly  associated  with  changes  in  GRS
(r  =  0.41,  p  <  0.01)  and  ACT  (r  =  −0.47,  p  <  0.01)  while  the
association  with  VAS  was  not  significant  (r  =  .14,  n.s.).
)  MID:  A  2  point  difference  or  change  in  RAPP  maximizes
sensitivity,  specificity,  and  the  number  of  individuals  cor-
rectly  classified  (Table  2).
No  significant  difference  was  reported  in  RAPP  scores3 .953  .686
2a .912  .833
1 .884  .931
a Cutoff point chosen.
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Figure  1  Frequency  distribution  o
 =  0.679;  Visit  2:  p  =  0.476).  Significant  associations  were
ound  between  age  and  RAPP  scores  (Spearman’s  correla-
ion.  Visit  1:  r  =  0.23,  p  =  0.005;  Visit  2,  r  = 0.31,  p  <  0.01).
The  frequency  distribution  of  answers  at  Visit  1  and  at
isit  2  shows  that  the  entire  scale  range  had  been  used
Fig.  1).
iscussion
n  daily  clinical  practice,  therapeutic  management  of
atients  with  comorbid  asthma  and  allergic  rhinitis  is  pri-
arily  decided  by  the  physician  according  to  the  patient’s
ymptoms  and  biological  parameters.  Little  emphasis  is
iven  to  the  patients’  perspective  of  the  impact  of  their
isease  and  its  treatment  upon  their  quality  of  life.  This  is
ainly  due  to  the  lack  of  simple  and  reliable  tools  for  assess-
ng  HRQoL  in  daily  routine;  the  questionnaires  available  are
oo  long  and  complex  for  routine  clinical  use.20
RAPP  has  been  validated  in  Italian  according  to  the  avail-
ble  guidance  to  properly  assess  the  patient’s  perspective  in
linical  practice21,22 and  a  cross-cultural  validation  is  needed
o  use  this  tool  in  everyday  practice  in  other  languages.
o  perform  this  process  we  selected  specific  tools  that  are
idely  used  for  the  validation  process  of  HRQoL  question-
aires  and  which  are  available  in  the  languages  needed  for
ll  countries  involved  in  this  international  study.  For  this
eason,  it  was  not  possible  to  assess  the  level  of  control
oth  in  asthma  and  AR.  In  fact,  although  tools  specifically
esigned  to  assess  control  are  available  for  asthma  (ACT),
hinitis  (ARCT)23 and  concomitant  asthma  and  rhinitis  (e.g.
ARAT),24 only  for  the  ACT  do  we  have  a  validated  version
n  Spain,  France,  Portugal,  Poland  and  the  Philippines.  For
his  reason,  we  decided  to  include  the  ACT  in  our  protocol
nd  to  evaluate  symptom  severity  instead  of  control  in  AR,
y  mean  of  VAS.  This  prospective  study  was  performed  to
alidate  the  Portuguese  version.
We  found  the  Portuguese  version  of  the  RAPP  to  be  reli-
ble  for  the  individual  assessment  of  HRQL.  Our  analyses
onfirmed  the  unidimensional  structure  of  the  tool  and  the
esults  of  factorial  analysis  explain  more  than  40%  of  vari-
nce,  proving  its  strong  validity.
In  terms  of  reliability,  the  Portuguese  version  of  the
APP  performed  well  in  the  present  validation  study,  with
C
T
PP  answers  at  Visit  1  and  at  Visit  2.
ronbach- values  over  the  recommended  0.70  threshold  for
he  overall  score.  Internal  consistency  results  were  generally
omparable  with,  or  better  than,  those  seen  for  the  original
nstrument.  Satisfactory  convergent  and  discriminant  valid-
ty  and  high  responsiveness  to  changes  were  confirmed.  The
ack  of  effect  of  demographic  characteristics  on  patients’
nswers  makes  the  questionnaire  appropriate  for  use  in
veryday  practice.
Since  asthma  and  rhinitis  symptoms  can  vary  over  time,
he  availability  of  a  patient-reported  outcomes  measure
hich  is  capable  of  mirroring  these  changes  is  significant.
s  in  the  original  version,  a  2  point  change  in  RAPP  score
dentified  a  HRQL  change  perceived  by  the  patient.
The  present  study  has  several  strengths.  First  of  all  it
onfirms  the  psychometric  properties  of  RAPP  in  a  language
ifferent  from  the  original  one.  Moreover  it  offers  the  possi-
ility  of  assessing  HRQoL  in  the  routine  clinical  management
f  Portuguese  patients  with  asthma  and  AR  and  to  compare
he  HRQoL  of  the  Portuguese-speaking  population  with  other
atients  from  different  countries.
One  limitation  of  our  study  is  the  generalizability  of  the
esults:  patient  selection  bias  cannot  be  excluded  since  the
atients  were  recruited  from  one  single  specialist  center
nd  the  sample  was  nonrandomized.  Moreover,  the  accept-
bility  of  the  RAPP  for  both  patients  and  physicians  and  the
dded  value  of  using  this  tool  in  clinical  practice  have  not
een  assessed.  These  limitations  may  be  addressed  through
urther  studies  including  other  settings  and  by  assessing
cceptability  and  clinical  relevance.
In  conclusion,  this  study  demonstrates  that  the  Por-
uguese  RAPP  version  is  suitable  for  use  among  asthma  and
llergic  rhinitis  patients  both  in  research  and  clinical  set-
ings.
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